Bisphosphonates for steroid induced osteoporosis

Area of Science:

• Endocrinology
• Rheumatology
• Metabolic Bone Disease

Background:

• Corticosteroid therapy is associated with significant bone loss, leading to osteoporosis.
• Corticosteroid-induced osteoporosis (CIOP) increases fracture risk.
• Bisphosphonates are a class of drugs known to inhibit bone resorption.

Purpose of the Study:

• To evaluate the effectiveness of bisphosphonates in preventing and treating CIOP.
• To assess the impact of bisphosphonates on bone mineral density (BMD) and fracture incidence in patients using corticosteroids.

Main Methods:

• A meta-analysis of 13 controlled clinical trials involving 842 adult patients on corticosteroid therapy (≥7.5 mg/day).
• Data extraction focused on changes in BMD at the lumbar spine and femoral neck, and fracture data.
• Statistical analysis included fixed effects models, with random effects models used for significant heterogeneity.

Main Results:

• Bisphosphonates significantly increased BMD at the lumbar spine by 4.3% (95% CI 2.7, 5.9) and at the femoral neck by 2.1% (95% CI 0.01, 3.8).
• A non-significant 24% reduction in the odds of spinal fractures was observed (OR 0.76; 95% CI 0.37, 1.53).

Conclusions:

• Bisphosphonates are effective in preserving bone density in patients with CIOP.
• While bone density improvements are noted, the current evidence is insufficient to confirm fracture prevention efficacy.
• Further research is needed to establish the role of bisphosphonates in reducing fracture risk in CIOP.